Clinical trialNCT01266460CompletedPhase 2Interventional

Vaccine Therapy in Treating Patients With Persistent or Recurrent Cervical Cancer

SponsorGynecologic Oncology GroupEnrollment54Cervical AdenocarcinomaCervical Adenosquamous CarcinomaCervical Squamous Cell Carcinoma, Not Otherwise SpecifiedRecurrent Cervical Carcinoma

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This phase II trial studies the side effects and how well vaccine therapy works in treating patients with cervical cancer that does not go to remission despite treatment (persistent) or has come back (recurrent). Vaccines therapy may help the body build an effective immune response to kill tumor cells.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Warner K Huh
NRG Oncology
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

24 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

University of Alabama at Birmingham Cancer Center
Birmingham, Alabama, United States
Saint Joseph'S Hospital and Medical Center
Phoenix, Arizona, United States
Uc San Diego Moores Cancer Center
La Jolla, California, United States
Los Angeles County-Usc Medical Center
Los Angeles, California, United States
Usc / Norris Comprehensive Cancer Center
Los Angeles, California, United States
Ucsf Medical Center-Mission Bay
San Francisco, California, United States
Ucsf Medical Center-Mount Zion
San Francisco, California, United States
Memorial Health University Medical Center
Savannah, Georgia, United States
University of Kansas Cancer Center
Kansas City, Kansas, United States
Johns Hopkins University/sidney Kimmel Cancer Center
Baltimore, Maryland, United States
Sinai Hospital of Baltimore
Baltimore, Maryland, United States
University of Michigan Comprehensive Cancer Center
Ann Arbor, Michigan, United States
Washington University School of Medicine
St Louis, Missouri, United States
Montefiore Medical Center-Einstein Campus
The Bronx, New York, United States
Carolinas Medical Center/levine Cancer Institute
Charlotte, North Carolina, United States
Case Western Reserve University
Cleveland, Ohio, United States
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, United States
Uh Seidman Cancer Center at Lake Health Mentor Campus
Mentor, Ohio, United States
University of Oklahoma Health Sciences Center
Oklahoma City, Oklahoma, United States
Oklahoma Cancer Specialists and Research Institute-Tulsa
Tulsa, Oklahoma, United States
Ut Southwestern/simmons Cancer Center-Dallas
Dallas, Texas, United States
University of Texas Medical Branch
Galveston, Texas, United States
Virginia Commonwealth University/massey Cancer Center
Richmond, Virginia, United States
Froedtert and the Medical College of Wisconsin
Milwaukee, Wisconsin, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Attenuated Live Listeria Encoding HPV 16 E7 Vaccine ADXS11-001

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 23 May 2011
Primary completion: 2 Oct 2018
Completion: 2 Oct 2018
Last update posted: 11 Sept 2020
Registered enrollment: 54
Registry id: NCT01266460

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.